Antiarrhythmic effects of beta3-adrenergic receptor stimulation in a canine model of ventricular tachycardia

Heart Rhythm

Volumn 5, Issue 2, 2008, Pages 289-297

  Zhou, Shengmei ^a   Tan, Alex Y ^a   Paz, Offir ^a   Ogawa, Masahiro ^a,c   Chou, Chung Chuan ^a   Hayashi, Hideki ^a   Nihei, Motoki ^a   Fishbein, Michael C ^b   Chen, Lan S ^d   Lin, Shien Fong ^a,c   Chen, Peng Sheng ^a,c  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Beta3 AR agonist; Sudden cardiac death; Ventricular arrhythmia

Indexed keywords

1,4 DIHYDROPYRIDINE RECEPTOR; 4 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL]PHENOXYACETIC ACID; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; SODIUM CALCIUM EXCHANGE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIARRHYTHMIC ACTIVITY; ARTICLE; BETA ADRENERGIC STIMULATION; CONTINUOUS INFUSION; CONTROLLED STUDY; DOG; ELECTROCARDIOGRAPHY MONITORING; FOLLOW UP; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE TACHYCARDIA; HEART WEIGHT; INCIDENCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QT INTERVAL; SUDDEN DEATH; SURVIVAL; WESTERN BLOTTING;

ADRENERGIC BETA-AGONISTS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; BLOTTING, WESTERN; DEATH, SUDDEN, CARDIAC; DOGS; ELECTROCARDIOGRAPHY; ETHANOLAMINES; HEART BLOCK; IMMUNOHISTOCHEMISTRY; MYOCARDIAL CONTRACTION; MYOCARDIAL INFARCTION; POTASSIUM CHANNELS; RECEPTORS, ADRENERGIC, BETA-3; RISK FACTORS; TACHYCARDIA, VENTRICULAR; TIME FACTORS;

EID: 38649126232     PISSN: 15475271     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hrthm.2007.10.014     Document Type: Article

References (25)

1. Yen T.T. Beta-agonists as antiobesity, antidiabetic and nutrient partitioning agents. Obes Res 3 Suppl 4 (1995) 531S-536S
2. Gauthier C., Tavernier G., Charpentier F., et al. Functional beta3-adrenoceptor in the human heart. J Clin Invest 98 (1996) 556-562
3. Cheng H.J., Zhang Z.S., Onishi K., et al. Upregulation of functional beta(3)-adrenergic receptor in the failing canine myocardium. Circ Res 89 (2001) 599-606
4. Kathofer S., Zhang W., Karle C., et al. Functional coupling of human beta 3-adrenoreceptors to the KvLQT1/MinK potassium channel. J Biol Chem 275 (2000) 26743-26747
5. Zhou S., Paz O., Cao J.-M., et al. Differential -adrenoceptor expression induced by nerve growth factor infusion into the canine right and left stellate ganglia. Heart Rhythm 2 (2005) 1347-1355
6. Moniotte S., Kobzik L., Feron O., et al. Upregulation of beta(3)-adrenoceptors and altered contractile response to inotropic amines in human failing myocardium. Circulation 103 (2001) 1649-1655
7. Dincer U.D., Bidasee K.R., Guner S., et al. The effect of diabetes on expression of beta1-, beta2, and beta3-adrenoreceptors in rat hearts. Diabetes 50 (2001) 455-461
8. Gauthier C., Langin D., and Balligand J.L. Beta3-adrenoceptors in the cardiovascular system. Trends Pharmacol Sci 21 (2000) 426-431
9. Verrier R.L. Beta3-adrenoceptor: friend or foe?. Heart Rhythm 2 (2005) 1356-1358
10. Cao J.-M., Chen L.S., KenKnight B.H., et al. Nerve sprouting and sudden cardiac death. Circ Res 86 (2000) 816-821
11. Swissa M., Zhou S., Gonzalez-Gomez I., et al. Long-term subthreshold electrical stimulation of the left stellate ganglion and a canine model of sudden cardiac death. J Am Coll Cardiol 43 (2004) 858-864
12. Shen Y.T., Cervoni P., Claus T., and Vatner S.F. Differences in beta 3-adrenergic receptor cardiovascular regulation in conscious primates, rats and dogs. J Pharmacol Exp Ther 278 (1996) 1435-1443
13. Zhou S., Chen L.S., Miyauchi Y., et al. Mechanisms of cardiac nerve sprouting after myocardial infarction in dogs. Circ Res 95 (2004) 76-83
14. Zhou S., Cao J.M., Tebb Z.D., et al. Modulation of QT interval by cardiac sympathetic nerve sprouting and the mechanisms of ventricular arrhythmia in a canine model of sudden cardiac death. J Cardiovasc Electrophysiol 12 (2001) 1068-1073
15. Weiss J.N., Karma A., Shiferaw Y., et al. From pulsus to pulseless: the saga of cardiac alternans. Circ Res 98 (2006) 1244-1253
16. Sipido K.R., Varro A., and Eisner D. Sodium calcium exchange as a target for antiarrhythmic therapy. Handb Exp Pharmacol (2006) 159-199
17. Kaumann A.J., and Molenaar P. Modulation of human cardiac function through 4 beta-adrenoceptor populations. Naunyn Schmiedebergs Arch Pharmacol 355 (1997) 667-681
18. Freemantle N., Cleland J., Young P., et al. Beta blockade after myocardial infarction: systematic review and meta regression analysis. Bmj 318 (1999) 1730-1737
19. Gottlieb S.S., McCarter R.J., and Vogel R.A. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 339 (1998) 489-497
20. Cao J.-M., Fishbein M.C., Han J.B., et al. Relationship between regional cardiac hyperinnervation and ventricular arrhythmia. Circulation 101 (2000) 1960-1969
21. Echt D.S., Liebson P.R., Mitchell L.B., et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 324 (1991) 781-788
22. Thomas R.F., Holt B.D., Schwinn D.A., et al. Long-term agonist exposure induces upregulation of beta 3-adrenergic receptor expression via multiple cAMP response elements. Proc Natl Acad Sci U S A 89 (1992) 4490-4494
23. Carpene C., Galitzky J., Collon P., et al. Desensitization of beta-1 and beta-2, but not beta-3, adrenoceptor-mediated lipolytic responses of adipocytes after long-term norepinephrine infusion. J Pharmacol Exp Ther 265 (1993) 237-247
24. Rouget C., Breuiller-Fouche M., Mercier F.J., et al. The human near-term myometrial beta 3-adrenoceptor but not the beta 2-adrenoceptor is resistant to desensitisation after sustained agonist stimulation. Br J Pharmacol 141 (2004) 831-841
25. Nantel F., Bonin H., Emorine L.J., et al. The human beta 3-adrenergic receptor is resistant to short term agonist-promoted desensitization. Mol Pharmacol 43 (1993) 548-555